Imaginepharma

Imagine Pharma's business revolves around its core discovery, the IMG-1 polypeptide, which has led to the creation of three distinct development platforms: Oral Delivery, Therapeutics, and Regenerative Medicine. These platforms are aimed at creating first-in-class programs to address various disease states in large, underserved markets. The company's business model encompasses multiple revenue paths, including the commercialization of a nutritional supplement, strategic partnerships, licensing agreements, and providing islet isolation services. In a significant milestone, the company was selected by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as an approved Islet Isolation Center, supplying research-grade human islets to major academic diabetes centers.

The company's product pipeline is diverse. The Oral Delivery platform is working on making injections a thing of the past by developing oral versions of biologics like erythropoietin and GLP-1 receptor agonists. The Therapeutics platform is developing treatments to accelerate healing for skin donor sites and diabetic wounds. Most notably, the Regenerative Medicine platform is pioneering a potential cure for Type 1 diabetes by using IMG-1 to regenerate and propagate insulin-producing islet cells from a patient's own pancreas for autologous transplantation. In October 2023, Imagine Pharma secured $32.5 million in a Series A funding round led by IP Investors LLC, bringing its total funding to $40 million to advance these programs.